Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial

By sjmartinez • November 14, 2024

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Epub ahead of print. PMID: 39523543.

Tags: COVID-19 drug therapy, EPIC-HR, Infectious Diseases, nirmatrelvir, Publications, ritonavir, Symptoms

Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings

Joseph Davey D, Dadan S, Wara N. Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings. Curr Opin HIV AIDS.[...]

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]